Can a Pre-Dose stop a dangerous immune reaction?

NCT ID NCT06447376

Recruiting now Disease control Sponsor: Taylor Brooks Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether giving siltuximab before epcoritamab can prevent cytokine release syndrome (CRS), a common and sometimes severe side effect. About 20 adults with non-Hodgkin lymphoma will receive siltuximab one hour before their first epcoritamab dose. Researchers will monitor for CRS and other side effects for at least 60 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siltuximab and epcoritamab
What this could lead to: If it works, this could point toward a way to prevent a serious side effect (cytokine release syndrome) in lymphoma patients receiving epcoritamab.
What could go wrong: This is a very small, early-phase trial with only 20 participants. It is designed to test safety and feasibility, not effectiveness. The approach may not work or may have unknown risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOKINE RELEASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome diffuse large B-cell lymphoma follicular lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOKINE RELEASE SYNDROME NON-HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
RECRUITING

Cleveland, Ohio, 44195, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.